Samsung and the Instituto do Coração of São Paulo University Medical School (Incor) Hospital das Clínicas have signed a partnership for a research project focused on remote monitoring of patients undergoing cardiac surgery. The partnership, with an initial duration of 14 months, aims to develop an auxiliary digital remote monitoring platform using the Galaxy Watch4 smartwatch to measure and collect data on cardiac patients during the preoperative and postoperative period of cardiovascular surgery. Patients’ vital signs, such as heart rate, blood pressure, oxygen saturation, sleep patterns, and electrocardiogram, will be analyzed in the study. In this way, it is possible to monitor the patient’s treatment, identify risks and intervene early if any relevant changes occur, thereby avoiding more serious complications.
According to the Brazilian Society of Cardiovascular Surgery (SBCCV), in Brazil, more than 100,000 cardiac surgeries are performed each year, requiring continuous observation during the postoperative period, in addition to highly complex medical care and quick decision-making. With this in mind, remote monitoring solutions will allow these patients to leave more quickly and in a more controlled manner, with important implications for public health. The partnership includes the use of a digital monitoring platform developed and integrated by the InCor IT Services team, supported by the Innovation Team (InovaInCor) and the Institute’s Clinical Team. Samsung is the sponsor of the project and is responsible for the data collection module of the smartwatches used in the study. The module was developed by Samsung’s Brazil R&D area in Campinas.
“Innovation is in Samsung’s DNA and we seek to apply it to our products and different usage environments, especially in healthcare where there are many opportunities. The partnership with InCor helps achieve one of the company’s goals, That is, beyond the usability limits of the devices we know today,” said Luis Guilherme Selber, innovation manager of Samsung Brazil’s R&D department. “The purpose of this research project is to allow patients to be assisted through the data collected by the Galaxy Watch4, with appropriate prior authorization. This platform will allow them to continue to be monitored during treatment, even outside the hospital setting, facilitating the identification of possible risk situations, enabling preventive medical action,” he explained.
The smartwatch used in the project is the Galaxy Watch4. Samsung’s latest model allows users to monitor their blood pressure1 and even detect irregular heartbeats with an electrocardiogram. The device also allows monitoring of oxygen saturation3, heart rate and sleep quality4. The Galaxy Watch4 is equipped with a sensor for assessing body composition through bioimpedance5 – a test that provides greater insight into the wearer’s overall health, including important measurements such as skeletal muscle, basal metabolic rate, body water and body fat percentage value.
“Innovation in healthcare is not just about new ideas, products and solutions, but how we integrate them into patient care and overcome challenges associated with participating in their treatment process, such as remote monitoring of some of the patient’s physiological parameters. This is one of the biggest motivations for working with Samsung – to build collaborative bridges to foster collaborative innovation,” commented Professor Professor, who led the project. Fabio B. Jatene, InCor Vice President and InovaInCor Coordinator.
With the results obtained at the end of the program, it is possible to replicate this technical solution in other settings of the Brazilian Health System (SUS), allowing it to be used for clinical follow-up of patients in a scalable manner. For these audiences, the benefits of the project are varied. Among them, reducing the risk of hospital environmental pollution, preventing sequelae and returning to routine after heart surgery. For hospitals, the benefit is economic in that it promotes long-term reductions in hotel and drug costs, as well as optimization of bed usage.
1 This application is not intended to replace traditional methods of diagnosis or treatment. Blood pressure data is for reference only. Users may not use the app to interpret or perform clinical actions based on the results of the app. Always seek out a doctor you trust if there are any changes or questions. To ensure accuracy, users must calibrate their devices at least every four weeks. Users should measure resting blood pressure as with a traditional cuff and avoid using it while exercising, smoking, or drinking alcohol. for reference only. Users may not use the app to interpret or perform clinical actions based on the results of the app. Requires pairing with a Galaxy smartphone running Android 7.0 or higher. Suitable for adults over 22 years old. Registered by ANVISA No. 81549259004
2 ECG functionality is only available in select markets. This app never looks for signs of a heart attack and is not intended to replace traditional methods of diagnosis or treatment. ECG applications are not intended to replace traditional diagnostic or therapeutic methods. The ECG app is not intended for users with known arrhythmias other than atrial fibrillation or users under the age of 22. Users should not interpret or take clinical action based on device output without consulting a qualified healthcare professional. Registered by ANVISA No. SAMSUNG HEALTH MONITOR – ECG APP: 81549259006
3 The “Blood Oxygenation” feature of the Samsung Health app on the watch is for general fitness and wellness purposes only. Measurements should not be used in the diagnosis and/or treatment of any medical condition. If you are concerned about your health, talk to your doctor. Monitoring blood oxygenation was defined as transcutaneous oxygen saturation. The normal level is about 95% to 100%. Factors such as strenuous exercise, oxygen levels in the air, altitude and various other health conditions can all cause lower readings. Requires pairing with a Galaxy smartphone running Android 7.0 or higher.
4 Measured values are for personal reference only. Advanced sleep features are for fitness and wellness purposes only and are not intended to detect, diagnose, or treat any health problem or disease. Consult your doctor for more information. Availability may vary by country or region.
5 For general health and fitness purposes only. It is not intended for the detection, diagnosis or treatment of any medical condition or disease. The measured values are provided for the user’s personal reference only. Consult your doctor for more information. If you are under the age of 20, the measurements may not be accurate. Do not measure your body composition if you have a pacemaker implant or other implanted medical device. Do not measure your body composition if you are pregnant.
About Samsung Electronics Co., Ltd.
Samsung inspires the world and shapes the future with transformative ideas and technologies. The company is redefining the world of TVs, smartphones, handhelds, tablets, digital devices, networking systems, memory, LSI systems, semiconductors and LED solutions. For the latest news, visit Samsung Newsroom https://news.samsung.com/uk.
About the Heart Institute (InCor)
Founded on January 10, 1977, InCor is one of seven institutions that make up the USP Medical School Clinical Hospital (HCFMUSP). In its 40 years, the institute has become one of the largest cardiorespiratory centers in the world in terms of volume of care and number of subspecialties gathered in one center. The institute is ranked 7th in the world for the most heart transplant centers and 1st in Brazil for lung and pediatric heart transplants. InCor is recognized as the best cardiology hospital in Brazil and Latin America, according to a 2021 evaluation by the US magazine Newsweek in partnership Statista, a German company for market and consumer data. The institute was also awarded a Who! of Innovation 2020 also ranked 8th among the 100 most innovative Brazilian companies in all industries as the most innovative company in the health sector.
About the Zebini Foundation
In order to financially support the Instituto do Coração, in 1978 Professor Euryclides de Jesus Zerbini and his collaborators created the Zerbini Foundation, a non-profit entity responsible for acquiring, managing and investing in the structure of InCor itself, and from regulations Get resources in the institution’s services in cardiology and pulmonology assistance, teaching, and research. The Zerbini Foundation is characterised by private law and public utilities, charities, charities and non-profits, with no shareholders or quota holders.
The InCor Innovation Projects Nucleus was created by the Zerbini Foundation together with the Instituto do Coração and is part of the innovation process management structure of the Hospital das Clínicas da FMUSP centered on InovaHC. Its purpose is to foster synergies between researchers, companies, development agencies and governments, while accelerating access to human, financial and technical resources to generate solutions in the life sciences sector – primarily related to cardiovascular and respiratory systems relevant to promote social and human well-being.